|
US3024257A
(en)
|
1961-04-10 |
1962-03-06 |
Frosst & Co Charles E |
Stable preparations of alkali metal salts of estrone sulfate
|
|
FR2340735A1
(fr)
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
|
IE52670B1
(en)
|
1981-03-03 |
1988-01-20 |
Leo Ab |
Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
|
|
DE3437232A1
(de)
|
1984-10-10 |
1986-04-17 |
Mack Chem Pharm |
Stabilisierte injektionsloesungen von piroxicam
|
|
US4782155A
(en)
|
1986-03-19 |
1988-11-01 |
Banyu Pharmaceutical Co., Ltd. |
Cephalosporin derivatives, processes for their preparation and antibacterial agents
|
|
SE8902076D0
(sv)
|
1989-06-09 |
1989-06-09 |
Pharmacia Ab |
Derivatives of quinoline-3-carboxanilide
|
|
HUT60458A
(en)
|
1991-02-01 |
1992-09-28 |
Sandoz Ag |
Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
|
|
US5139878A
(en)
|
1991-08-12 |
1992-08-18 |
Allied-Signal Inc. |
Multilayer film constructions
|
|
US5540934A
(en)
|
1994-06-22 |
1996-07-30 |
Touitou; Elka |
Compositions for applying active substances to or through the skin
|
|
CH687615A5
(de)
|
1994-09-07 |
1997-01-15 |
R W Johnson Pharmaceutical Res |
Tropen-Verpackung.
|
|
US5912349A
(en)
|
1997-01-31 |
1999-06-15 |
Pharmacia & Upjohn Company |
Process for the preparation of roquinimex
|
|
US20030124187A1
(en)
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
|
US6077851A
(en)
|
1998-04-27 |
2000-06-20 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9801474D0
(sv)
*
|
1998-04-27 |
1998-04-27 |
Active Biotech Ab |
Quinoline Derivatives
|
|
SE9802550D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6133285A
(en)
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6121287A
(en)
|
1998-07-15 |
2000-09-19 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802549D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
EE200100660A
(et)
|
1999-06-07 |
2003-04-15 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake
|
|
SE0002320D0
(sv)
|
1999-10-25 |
2000-06-21 |
Active Biotech Ab |
Malignant tumors
|
|
PL199781B1
(pl)
|
1999-10-25 |
2008-10-31 |
Active Biotech Ab |
Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
|
|
JP2002031610A
(ja)
|
2000-07-14 |
2002-01-31 |
Ajinomoto Co Inc |
生体分子複合体の界面残基を同定する方法
|
|
US6307050B1
(en)
|
2000-08-29 |
2001-10-23 |
R. T. Alamo Venture I Llc |
Method of synthesizing flosequinan from 4-fluoroanthranilic acid
|
|
US6802422B2
(en)
|
2000-12-12 |
2004-10-12 |
Multi-Comp, Inc. |
Sealed blister assembly
|
|
US6706733B2
(en)
|
2001-05-08 |
2004-03-16 |
Dainippon Ink And Chemicals, Inc. |
Quinolinone derivative formulation and its production method
|
|
US20030119826A1
(en)
|
2001-09-24 |
2003-06-26 |
Pharmacia Corporation |
Neuroprotective treatment methods using selective iNOS inhibitors
|
|
US7560557B2
(en)
|
2002-06-12 |
2009-07-14 |
Active Biotech Ag |
Process for the manufacture of quinoline derivatives
|
|
US6875869B2
(en)
|
2002-06-12 |
2005-04-05 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
SE0201778D0
(sv)
|
2002-06-12 |
2002-06-12 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
ITMI20021726A1
(it)
|
2002-08-01 |
2004-02-02 |
Zambon Spa |
Macrolidi ad attivita' antiinfiammatoria.
|
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
US20040253305A1
(en)
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
|
EP1694308A1
(en)
|
2003-10-30 |
2006-08-30 |
Lupin Ltd. |
Stable formulations of ace inhibitors and methods for preparation thereof
|
|
SE0400235D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
|
US8314124B2
(en)
|
2004-02-06 |
2012-11-20 |
Active Biotech Ab |
Crystalline salts of quinoline compounds and methods for preparing them
|
|
CA2613678A1
(en)
|
2005-06-02 |
2006-12-07 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
BRPI0617477A2
(pt)
|
2005-10-19 |
2011-07-26 |
Teva Pharma |
mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
|
|
US20070218062A1
(en)
|
2006-03-16 |
2007-09-20 |
Genentech, Inc. |
Methods of treating lupus using CD4 antibodies
|
|
CN101466379B
(zh)
|
2006-06-12 |
2012-10-31 |
泰华制药工业有限公司 |
稳定的拉喹莫德的制剂
|
|
BRPI0715950A2
(pt)
|
2006-08-17 |
2013-07-30 |
Univ Chicago |
tratamento de doenÇas inflamatàrias
|
|
US20100260716A1
(en)
|
2007-10-23 |
2010-10-14 |
Ucb Pharma Gmbh |
Compounds for treating demyelination conditions
|
|
WO2009082471A1
(en)
|
2007-12-20 |
2009-07-02 |
Teva Pharmaceutical Industries, Ltd. |
Stable laquinimod preparations
|
|
US8354428B2
(en)
|
2008-07-01 |
2013-01-15 |
Actavis Group Ptc Ehf |
Solid state forms of laquinimod and its sodium salt
|
|
AU2009288108B2
(en)
*
|
2008-09-03 |
2013-10-17 |
Teva Pharmaceutical Industries, Ltd. |
2-oxo-1,2-dihydro-quinoline modulators of immune function
|
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
US20100260755A1
(en)
*
|
2009-04-09 |
2010-10-14 |
Medicinova, Inc. |
Ibudilast and immunomodulators combination
|
|
NZ597378A
(en)
|
2009-06-19 |
2014-08-29 |
Teva Pharma |
Treatment of multiple sclerosis with laquinimod
|
|
BR112012002124A2
(pt)
|
2009-07-30 |
2015-09-15 |
Teva Pharma |
tratamento da doença de crohn com laquinimode.
|
|
WO2011019375A1
(en)
|
2009-08-10 |
2011-02-17 |
Teva Pharmaceutical Industries Ltd. |
Treatment of bdnf-related disorders using laquinimod
|
|
WO2011086470A1
(en)
*
|
2010-01-13 |
2011-07-21 |
Ramot At Tel-Aviv University Ltd |
Treatment of multiple sclerosis
|
|
EA201290860A1
(ru)
|
2010-03-03 |
2013-04-30 |
Тева Фармасьютикал Индастриз Лтд. |
Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
|
|
US20110217295A1
(en)
|
2010-03-03 |
2011-09-08 |
Asi Haviv |
Treatment of lupus arthritis using laquinimod
|
|
JP5934202B2
(ja)
|
2010-07-09 |
2016-06-15 |
テバ ファーマシューティカル インダストリーズ リミティド |
５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用
|
|
AU2011274496B2
(en)
|
2010-07-09 |
2016-03-10 |
Teva Pharmaceutical Industries Ltd. |
Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
|
|
EP2463289A1
(en)
*
|
2010-11-26 |
2012-06-13 |
Almirall, S.A. |
Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
|
|
PE20140872A1
(es)
|
2010-12-07 |
2014-08-09 |
Teva Pharma |
Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple
|
|
EP2537517A1
(en)
*
|
2011-06-22 |
2012-12-26 |
Active Biotech AB |
Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
|
|
SG10201606191PA
(en)
|
2011-07-28 |
2016-09-29 |
Teva Pharma |
Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
|
|
HK1198278A1
(en)
|
2011-07-28 |
2015-03-27 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
|
|
SG11201401330YA
(en)
|
2011-10-12 |
2014-05-29 |
Teva Pharma |
Treatment of multiple sclerosis with combination of laquinimod and fingolimod
|
|
WO2013116657A1
(en)
|
2012-02-03 |
2013-08-08 |
Teva Pharmaceutical Industries Ltd. |
USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
|
|
MX2014009889A
(es)
|
2012-02-16 |
2014-11-13 |
Teva Pharma |
N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
|
|
US20130259856A1
(en)
|
2012-03-27 |
2013-10-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
|
|
TW201804997A
(zh)
|
2012-05-02 |
2018-02-16 |
以色列商泰瓦藥品工業有限公司 |
高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
|
|
TW201350467A
(zh)
*
|
2012-05-08 |
2013-12-16 |
Teva Pharma |
Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
|
|
WO2014004733A1
(en)
|
2012-06-26 |
2014-01-03 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
AR091706A1
(es)
|
2012-07-11 |
2015-02-25 |
Teva Pharma |
Formulaciones de laquinimod sin agentes alcalinizantes
|
|
UY34896A
(es)
|
2012-07-12 |
2014-02-28 |
Teva Pharma |
Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
|
|
TW201410243A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
TW201410244A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|